SCHEMBL5535882

SCHEMBL5535882

O=C(Cl)N1CCC(c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM5 P08912 1/20 0.51
CHRM1 P11229 1/20 0.51
CHRM3 P20309 1/20 0.51
HTR2C P28335 2/20 0.50
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
P2RY14 Q15391 4/20 0.47
ADRB3 P13945 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
DRD5 P21918 1/20 0.47
HTR1D P28221 1/20 0.47
HTR1E P28566 1/20 0.47
TSPO P30536 1/20 0.47
ADRA1A P35348 1/20 0.47
DRD3 P35462 1/20 0.47
HTR5A P47898 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636716 0.86 LIPE (0.52) LIPECHRM2CHRM5CHRM1CHRM3
SCHEMBL21425207 0.84 PROKR1 (0.56) HTR2CF2R
SCHEMBL1761033 0.82 DRD2 (0.56) HTR2CMGLL
SCHEMBL16963363 0.80 CCR1 (0.57) KCNH2HSD11B1CCR1
SCHEMBL8220312 0.80 LIPE (0.50) LIPECHRM2CHRM5CHRM1CHRM3
SCHEMBL2297690 0.79 P2RY14 (0.64) LIPEP2RY14
SCHEMBL15840446 0.79 EPHX2 (0.62) CHRM2CHRM5CHRM1CHRM3P2RY14
SCHEMBL1193744 0.78 KCNH2 (0.56) KCNH2HSD11B1CA12CA2CA9
SCHEMBL5545281 0.78 EPHX2 (0.61) LIPECNR1
SCHEMBL5544096 0.78 RHOC (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LIPE 4705/4885CHRM2 862/4885CHRM5 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.